Hylenex Recombinant is a drug owned by Halozyme Therapeutics Inc. It is protected by 1 US drug patent filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2027. Details of Hylenex Recombinant's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7767429 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
Sep, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Hylenex Recombinant's patents.
Latest Legal Activities on Hylenex Recombinant's Patents
Given below is the list of recent legal activities going on the following patents of Hylenex Recombinant.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 01 Dec, 2021 | US7767429 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Jan, 2018 | US7767429 (Litigated) |
| Change in Power of Attorney (May Include Associate POA) Critical | 04 Apr, 2011 | US7767429 (Litigated) |
| Correspondence Address Change Critical | 30 Mar, 2011 | US7767429 (Litigated) |
| Sequence Moved to Public Database | 09 Aug, 2010 | US7767429 (Litigated) |
| Recordation of Patent Grant Mailed Critical | 03 Aug, 2010 | US7767429 (Litigated) |
| Patent Issue Date Used in PTA Calculation Critical | 03 Aug, 2010 | US7767429 (Litigated) |
| Issue Notification Mailed Critical | 14 Jul, 2010 | US7767429 (Litigated) |
| Printer Rush- No mailing | 25 Jun, 2010 | US7767429 (Litigated) |
| Pubs Case Remand to TC Critical | 22 Jun, 2010 | US7767429 (Litigated) |
US patents provide insights into the exclusivity only within the United States, but Hylenex Recombinant is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Hylenex Recombinant's family patents as well as insights into ongoing legal events on those patents.
Hylenex Recombinant's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Hylenex Recombinant's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 23, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Hylenex Recombinant Generics:
There are no approved generic versions for Hylenex Recombinant as of now.
About Hylenex Recombinant
Hylenex Recombinant is a drug owned by Halozyme Therapeutics Inc. Hylenex Recombinant uses Hyaluronidase Recombinant Human as an active ingredient. Hylenex Recombinant was launched by Halozyme Therap in 2005.
Approval Date:
Hylenex Recombinant was approved by FDA for market use on 02 December, 2005.
Active Ingredient:
Hylenex Recombinant uses Hyaluronidase Recombinant Human as the active ingredient. Check out other Drugs and Companies using Hyaluronidase Recombinant Human ingredient
Dosage:
Hylenex Recombinant is available in injectable form for injection use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 150 UNITS/ML | INJECTABLE | Prescription | INJECTION |